Application of Nano-Delivery Systems in Lymph Nodes for Tumor Immunotherapy

Abstract

Immunotherapy has become a promising research “hotspot” in cancer treatment. “Soldier” immune cells are not uniform throughout the body; they accumulate mostly in the immune organs such as the spleen and lymph nodes (LNs), etc. The unique structure of LNs provides the microenvironment suitable for the survival, activation, and proliferation of multiple types of immune cells. LNs play an important role in both the initiation of adaptive immunity and the generation of durable anti-tumor responses. Antigens taken up by antigen-presenting cells in peripheral tissues need to migrate with lymphatic fluid to LNs to activate the lymphocytes therein. Meanwhile, the accumulation and retaining of many immune functional compounds in LNs enhance their efficacy significantly. Therefore, LNs have become a key target for tumor immunotherapy. Unfortunately, the nonspecific distribution of the immune drugs in vivo greatly limits the activation and proliferation of immune cells, which leads to unsatisfactory anti-tumor effects. The efficient nano-delivery system to LNs is an effective strategy to maximize the efficacy of immune drugs. Nano-delivery systems have shown beneficial in improving biodistribution and enhancing accumulation in lymphoid tissues, exhibiting powerful and promising prospects for achieving effective delivery to LNs. Herein, the physiological structure and the delivery barriers of LNs were summarized and the factors affecting LNs accumulation were discussed thoroughly. Moreover, developments in nano-delivery systems were reviewed and the transformation prospects of LNs targeting nanocarriers were summarized and discussed.

A new era in cancer treatment: harnessing ZIF-8 nanoparticles for PD-1 inhibitor delivery

“…34,[78][79][80][81] Targeted delivery systems have emerged as a game-changer in the field of immunotherapy, offering a multitude of advantages. 17,82,83 One of the key benefits is the enhancement of the therapeutic index, a measure of a drug's safety in relation to its effectiveness. 84,85 By increasing drug concentrations specifically at the tumor site and reducing off-target effects, targeted delivery systems can significantly improve this index.…”

“…84,85 By increasing drug concentrations specifically at the tumor site and reducing off-target effects, targeted delivery systems can significantly improve this index. 17,82,83 Moreover, these systems pave the way for the administration of lower drug doses. This approach not only minimizes systemic toxicity but also improves patient tolerability, striking a balance between efficacy and safety.…”

Immunomodulatory activities and biomedical applications of melittin and its recent advances

“…This can be achieved through the use of nanoparticle (NP)-based drug delivery systems that can selectively target cancer cells. [47,51,52] In addition, combination therapies involving MLT and other anticancer agents such as chemotherapy drugs or radiotherapy and using genetic engineering techniques to create MLT-producing cells have also been explored as a way to enhance the therapeutic efficacy of MLT while reducing its toxicity to healthy cells. [53,54] This review aims to underline the MLT properties and applications.…”

Metal–Organic Framework Nanomaterials as a Medicine for Catalytic Tumor Therapy: Recent Advances

“…The field of nanomedicine has witnessed rapid advancements via the development of sophisticated nanomaterials and a deeper understanding of tumor pathogenesis. The application of nanomaterials in tumor therapy is garnering increased attention [4,5]. Rationally designed nanomaterials can significantly improve the stability of drugs in complex physiological environments and their accumulation at tumor sites by increasing permeability and retention efficacy [6][7][8].…”